The Daily Papule

Meeting abstracts

BAD 2026

British Association of Dermatologists · Manchester, 30 June – 2 July 2026

639 abstracts, published in BJD on 26 June 2026.

  1. BH07

    Early real-world insights from GRASS-UK: pilot data from a prospective alopecia areata register

    Shakeel M, Meah N, … senior author Harries M

  2. BH15

    Ritlecitinib for alopecia areata: all-Wales audit

    Caesar J, Goodwin R

  3. BH20

    An unintended sequela of hair regrowth: severe Janus kinase inhibitor-associated acneiform eruption in alopecia areata

    Adiotomre M, King T

  4. BH21

    Efficacy and safety of oral Janus kinase inhibitors in the treatment of alopecia areata: a systematic review and meta-analysis

    Morriss S, Foo CH, … senior author Bhoyrul B

  5. BH22

    Consultant dermatologists’ experiences and observations on the use of ritlecitinib for alopecia areata: all-Wales survey

    Caesar J, Goodwin R

  6. BH24

    Are we using Janus kinase inhibitors safely and effectively? A regional audit of ritlecitinib prescribing for alopecia areata in North Wales

    Malik B, Williams A, … senior author Alsaadi D

  7. BH25

    Frontal fibrosing alopecia arising on a background of vitiligo: a case presentation and review of the literature

    Biswas S, Rouhani N, Kubba F

  8. BH31

    Ritlecitinib for severe alopecia areata: does regional prescribing match national guidance?

    Eraifej N, Peers V, … senior author Meah N

  9. BI03

    An out-of-place mucosal virus causing cutaneous crisis: a rare case of disseminated human papillomavirus-6 infection during upadacitinib therapy for atopic dermatitis

    Moon E, Shanshal M

  10. BI35

    Skin-focused safety measures in upadacitinib-treated inflammatory bowel disease: a service evaluation

    Kuladeva D, Zhen Yam AI, Paul Seenan J

  11. BI43

    A high-risk squamous cell carcinoma developing in a patient with eczema treated with upadacitinib

    Murphy L, McCafferty B, … senior author McKenna D

  12. O12

    Efficacy of ruxolitinib cream for the treatment of moderate atopic dermatitis across anatomic regions in the phase IIIb TRuE-AD4 study

    Agius E, Peris K, … senior author Eleftheriadou V

  13. P014

    Remibrutinib improves dermatology-related quality of life in patients with chronic spontaneous urticaria regardless of baseline disease severity in the phase III REMIX-1 and REMIX-2 studies

    Ardern-Jones MR, Reed J, … senior author Saini S

  14. P016

    A case of metastatic Crohn disease successfully treated with upadacitinib

    Partridge L, Jaulim SZ

  15. P100

    Topical Janus kinase inhibitors for lichenoid disorders: a systematic review of the current evidence landscape

    Shanshal M, Uthayakumar A, Bali R

  16. P102

    Repigmentation and disease stabilization across medical, phototherapeutic and surgical treatments in vitiligo: a systematic review and meta-analysis

    Parsad D, Kumaran S, Keshavamurthy V

  17. P116

    Differential risk of incident and recurrent erythrodermic psoriasis in patients receiving systemic therapies: cohort analyses from the British Association of Dermatologists Biologics and Immunomodulators Register

    Al-Janabi A, Alabas O, … senior author Warren RB

  18. P120

    Improvements in signs of chronic hand eczema with delgocitinib cream as assessed by the Hand Eczema Symptom Diary: pooled analysis of the phase III DELTA 1 and 2 trials

    Warren RB, Johnston GA, … senior author Woolf R

  19. P126

    Treatment journey in patients with atopic dermatitis on abrocitinib: real-world evidence from the DREAM TO TREAT AD (D2T AD) Consortium

    Prieto-Merino D, Gribaleva E, … senior author Flohr C

  20. P129

    A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: predictors of treatment response

    Li D, Singhal G, … senior author Andrew K

  21. P130

    Oral tofacitinib in acquired dermal macular hyperpigmentation: a retrospective study

    Bansal S, Vashisht S, Alam S

  22. P131

    A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: safety and treatment persistence

    Wong V, Li D, … senior author Andrew K

  23. P135

    Advanced therapies in pyoderma gangrenosum: insights from a UK dermatology centre

    Sebastian N, Lewis H, Fremlin G

  24. P141

    Maintaining disease control on systemic immunomodulatory therapy for psoriasis: a systematic review and meta-analysis

    Ye W, Corbett M, … senior author Mahil S

  25. P146

    A multicentre retrospective study evaluating the real-world efficacy and safety of ritlecitinib in the treatment of alopecia areata

    Boyd G, McMorrow H, … senior author Hoey S

  26. P151

    A multicentre real-world evaluation of ritlecitinib in severe alopecia areata: patient-reported outcome measures

    Bhanot R, Li D, … senior author Andrew K

  27. P152

    Baseline characteristics and treatment effectiveness of abrocitinib in moderate-to-severe atopic dermatitis: results from the UK-Irish Atopic eczema Systemic TherApy Register (A-STAR) cohort analysis

    Raymond B, Patel M, Sahin B

  28. P154

    Patient perceptions and preferences regarding systemic medicines for moderate-to-severe eczema

    Harvey J, Shall E, … senior author Leighton P

  29. P157

    Oral tofacitinib vs. betamethasone oral minipulse therapy in progressive nonsegmental vitiligo: a randomized investigator-blinded clinical trial

    KM S, Ramam M, … senior author Gupta V

  30. P165

    Real-world experience of ritlecitinib for the treatment of alopecia areata from an alopecia clinic in a large tertiary dermatology centre

    Thanki M, McGuire A, … senior author Tziotzios C

  31. PA01

    ‘Too young to clot?’ Extensive lower-limb thrombosis, phlegmasia alba and distal-limb ischaemia in a young person receiving ritlecitinib for alopecia areata

    Gavin Fong WC, Satchwell F, … senior author Ravenscroft J

  32. PS58

    Management approaches and assessment of treatment response in patients with topical steroid withdrawal

    Vora S, McGrath C, … senior author Gkini MA

  33. SG14

    JAK of all trades: successful use of upadacitinib in treatment of epidermolysis bullosa pruriginosa

    Yiu D, Bardhan A, … senior author Heagerty A

That's every abstract.